Your trusted source for investing success

Tag: pharmaceutical

Will Trump Bring Back the Gold Standard? Could He?

One thing is for sure, Trump is having a significant impact on the markets. Gold in particular! Get our Report (value of $49) for FREE. Limited time offer. No credit card required.   Get My Free Report
Click here to download for free

Aeolus Announces Publication of Data

Aeolus Pharmaceuticals shared the publication of a study in a peer-reviewed journal demonstrating that AEOL 10150 improves survival and protects against brain damage and oxidative stress caused by seizures after pilocarpine exposure.

What is Lithium Carbonate?

What is Lithium Carbonate?

Lithium production numbers are often broken down in terms of lithium carbonate equivalent. But what is lithium carbonate? Find out here.

CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its financial results for the three and nine months ended July 31, 2017.

Highlights

Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.

DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the initiation of a Phase 2 clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, James

Alliance Growers Signing European Finance Exclusive

Alliance Growers Signing European Finance Exclusive

Alliance Growers Corp.(CSE:ACG; FWB:1LA)  is pleased to announce that in connection with the acquisition of the land for the Cannabis Botany Centre, Alliance is finalizing an exclusive financing proposal with a Western European Financing group with offices in Amsterdam, New York, London and Germany.

The financing of Alliance Growers projects is

Will Trump Bring Back the Gold Standard? Could He?

One thing is for sure, Trump is having a significant impact on the markets. Gold in particular! Get our Report (value of $49) for FREE. Limited time offer. No credit card required.   Get My Free Report
Click here to download for free
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/emerald-health-therapeutics-scientific-advisors-publish-research-discovery/